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CASE REPORT
A novel VARS2 gene variant in a patient with epileptic encephalopathy
Lucija Ruzmana, Ivana Kolica, Jelena Radic Nisevica,b, Antonija Ruzic Barsicc, Ingrid Skarpa Prpicd and
Igor Prpica,b
aChild Neurology and Child Psychiatry Department, Pediatric Clinic, Clinical Hospital Center Rijeka, Rijeka, Croatia; bUniversity of Rijeka,
School of Medicine Rijeka, Rijeka, Croatia; cRadiology Department, Thalassoterapia Opatija, Opatija, Croatia; dNeurology Clinic, Clinical
Hospital Center Rijeka, Rijeka, Croatia
ABSTRACT
Background: Mitochondrial disorders are heterogeneous clinical syndromes caused by defective activ-
ity in the mitochondrial respiratory chain, resulting in a faulty oxidative phosphorylation system. These
inherited disorders are individually rare, and furthermore they are phenotypic variables. The genetically
characterized mitochondrial disorders are rarely associated with epileptic encephalopathies.
Case presentation: We present the clinical phenotype, biochemical analysis, and electrographic and
neuro-radiological features of a 5-month-old girl with epileptic encephalopathy, microcephaly, severe
psychomotor delay, hypertrophic cardiomyopathy, and abnormal MRI scan. Using whole-genome
sequencing technique, compound heterozygous mutations of the VARS2 gene were revealed, with
one previously unreported frameshift mutation.
Conclusion: Our report extends the phenotypic spectrum of VARS2-related disorders with an initial
presentation of epileptic encephalopathy and early death due to malignant arrhythmia.
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Introduction
Mitochondrial disorders are heterogeneous clinical syn-
dromes caused by defective activity in the mitochondrial
respiratory chain (MRC), resulting in a faulty oxidative phos-
phorylation system (OXPHOS) (1), associated with a broad
range of nuclear and mitochondrial gene mutations. These
inherited disorders are rare and phenotypically variable, and
thus generally unfamiliar to clinicians. Epileptic encephalopa-
thies (EE) constitute a heterogeneous group of disorders
characterized by intractable seizures with specific abnormal-
ities on electroencephalography (EEG) and severe develop-
mental delay or regression (2); however, a clearly defined
aetiology and a diagnostic algorithm for these clinical enti-
ties have not been fully established.
In our case study we present a clinical phenotype, a bio-
chemical analysis, as well as electrographic and neuroradio-
logical features of a patient with EE. A genetic analysis
revealed an MRC defect.
Methods
Acquisition of a clinical case
We made a comprehensive evaluation of our patient, includ-
ing molecular genetics investigations. The patient’s parents
signed an informed consent in agreement with the
Declaration of Helsinki.
Molecular genetics
Genomic DNA from the proband, father, and mother was iso-
lated from peripheral blood samples, and whole-exome
sequencing (WES) was completed. WES, bioinformatic ana-
lysis, variant confirmation, and segregation analysis was per-
formed in the CeGaT GmbH laboratory (T€ubingen, Germany).
Coding and flanking intronic regions were enriched using
the Agilent in solution technology and were sequenced
using the Illumina HiSeq/NovaSeq system (Illumina Inc., San
Diego, California, USA). Variants (SNVs/small indels) with a
minor allele frequency (MAF) <1.5% were evaluated. Known
disease-causing variants (according to HGMD) were evaluated
up to 5% MAF. The MAF were taken from the 1000
Genomes, dsSNP, GnomAD, and in-house database. For the
index case, 95.61% of the targeted regions were covered by
a minimum of 30 high-quality sequencing reads per base. All
filtered variants were further analysed using Mutation Taster,
fathmm, Mutation Assessor, SIFT, fathmm-MKL coding, LRT,
and PROVEAN for pathogenicity prediction. Two algorithms
were applied (3) for assessments of the consequences of var-
iants on splicing. WES identified compound heterozygous
mutations in the VARS2 gene (NM_001167734.1) in our
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patient. Both parents are heterozygous carriers of variants
in VARS2.
Results
A female child was born at term after an uneventful preg-
nancy and delivery. She was the first child from the first
pregnancy of healthy non-consanguineous parents. The fam-
ily history was unremarkable. The birth weight, length, and
head circumference were in accordance with the gestational
age (4030 g, 51 cm, and 34 cm, respectively). Computed tom-
ography (CT) was performed at one month of age because
of failure of head growth (50th percentile at birth and 10th
after neonatal period). Craniosynostosis was excluded, with
no other pathological findings. Neurohabilitation was started
due to delayed acquisition of milestones.
At 5months of age she developed infantile spasms con-
sistent with hypsarrhythmia on EEG studies. Clinical examina-
tions showed microcephaly with ‘pear-shaped face’,
hypertelorism, and a wide nasal bridge. Global motor devel-
opment was delayed by 2–3months. Language and social
skills were in accordance with the patient’s age. Laboratory
findings revealed an increased concentration of alanine in
plasma (537 lmol/L, normal range 100–439 lmol/L) and cere-
brospinal fluid (36.1 lmol/L, normal range 19.9–31.3 lmol/L),
as well as mildly elevated concentrations of lactate in plasma
(2.0–5.4mmol/L, normal range 0.33–2.0mmol/L) and cerebro-
spinal fluid (3.0mmol/L, normal range 1.1–2.8mmol/) indica-
tive of mitochondrial disorder, while others were normal.
Magnetic resonance imaging (MRI) performed at that time
revealed diffuse cerebral atrophy with more prominent hypo-
plasia of the cerebellum (especially vermis), brainstem, and
corpus callosum (Figure 1(A)).
At the age of 6months multiple seizure types (mastica-
tion, eyelid and lip twitching, myoclonic seizures of the trunk
and extremities, tonic and clonic seizures) were noticed.
Treatment attempts with several antiepileptic drugs including
folic acid, cholecalciferol, pyridoxine and modified Atkins diet
were not successful. EEG studies showed continuous burst–
suppression pattern. All in all, the clinical status of the child
developed into EE. Microcephaly, severe global hypotonia,
failure to thrive, and feeding and breathing difficulties were
more and more pronounced. Pendular nystagmus and
oedema of hands and feet were periodically noticed.
Echocardiography showed hypertrophic obstructive cardio-
myopathy with fast progression, and atenolol treatment
was initiated.
Figure 1. (A) First MRI scan, age 5months. Sagittal T1-weighted and coronal T2-weighted imaging showing diffuse white matter reduction, marked cerebral and
cerebellar atrophy, corpus callosum thinning, and brainstem hypoplasia. (B) MRI scan, age 9months. Coronal T2-weighted imaging showing marked progression of
cerebral and cerebellar atrophy and ventriculomegaly (dominantly left occipital ventricle) due to diffuse white matter necrosis, while MRI spectroscopy showed
markedly increased myoinositol peak, increased lactate peak, and reduced N-acetyl aspartate peak.
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Genetic analysis was performed at the age of 9months,
and it revealed compound heterozygous mutations of the
VARS2 gene: previously reported pathogenic variant
(c.1100C>T; p.Thr367Ile) transmitted from the father and one
unreported frameshift mutation (c.603_606dupGATG;
p.Arg203Aspfs37) transmitted from the mother. An add-
itional MRI with spectroscopy showed a further significant
loss of the brain parenchyma and a high lactate peak
(Figure 1(B)).
A multidisciplinary treatment approach was applied to
treat the neurologic, cardiac, respiratory, and gastrointestinal
complications. In accordance with the established diagnosis,
treatment with L-carnitine and coenzyme Q10 was initiated.
Despite multiple supportive and symptomatic treatment regi-
mens, the child died of malignant arrhythmia at the age
of 10months.
Discussion
Combined oxidative phosphorylation deficiency 20
(COXPD20) (OMIM #615917) is an autosomal recessive mito-
chondrial encephalocardiomyopathy caused by variants in
the VARS2 gene (OMIM #612802) located on chromosome
6p21 (https://www.omim.org/entry/615917). The VARS2 gene
contains 30 exons and encodes mitochondrial valyl tRNA-
synthetase, which participates in mitochondrial protein syn-
thesis (4). Despite the estimated prevalence of MRC defects
being 1 in 5000 live births, it is often difficult to find the
molecular basis. The underlying genetic basis is not possible
to identify in 40% to 70% of the patients, even though there
is biochemical evidence of MRC defects (5). Presently, there
are 10 reported pathogenic variants in the VARS2 gene
(https://www.ncbi.nlm.nih.gov/clinvar/?term=VARS2[all]).
When considering our patient in comparison with previ-
ously reported patients with VARS2 mutations (5–10), it
appears that the main phenotypic features are seizures, vari-
ous degrees of developmental delay, facial dysmorphism,
brain atrophy, and cardiomyopathy. The main clinical fea-
tures, biochemical studies, and molecular findings are shown
in Table 1.
Bruni et al. (10) elaborated clinical, biochemical, and
molecular features in 13 patients from 9 families diagnosed
by WES. Two previously reported cases by Taylor et al. (5)
and by Pronicka et al. (9) were also included. Bruni et al. (10)
presented a new homozygous (c.1258G>A; p.Ala420Thr) vari-
ant and four new compound heterozygous variants, along
with already known pathogenic variants (Table 1). The study
found the mutant VARS2 allele c.1100C>T; p.Thr367Ile the
most common—in six patients in homozygous and in five
patients in heterozygous states. Laboratory findings implied
a mitochondrial disease, while the EEG and brain MRI of
these patients did not show any disease-characteristic pat-
tern. The common problem in these patients (n¼ 11/17) is
hypertrophic cardiomyopathy, with only a few patients not
being affected. The c.1100C>T; p.Thr367Ile variant is consid-
ered to have less of an effect on the heart (10). Alsemari
et al. (11) published a study describing four patients with
Angelman-like syndrome and mutation in the VARS2 gene,
providing new insight into genotype–phenotype correlation.
To date, our case is one of the 17 described cases of
severe infantile mitochondrial disorder associated with
VARS2 pathogenic variants. The phenotypic spectrum of
VARS2-related gene variants is complex, and no clear genoty-
pe–phenotype correlations have been established. Therefore,
a detailed description of phenotype related to specific muta-
tions is of great importance. Our report extends the pheno-
typic spectrum of VARS2-related disorders in the context of
EE, severe neurodevelopmental delay, abnormal brain MRI
scan, and one novel frameshift mutation
(c.603_606dupGATG; p.Arg203Aspfs37) in VARS2
(NM_001167734.1). With the exception of supportive care,
currently no disease-modifying treatment exists for
the disease.
The genetically characterized mitochondrial disorders are
rarely associated with EE, with very few clinical reports avail-
able (12). A timely evaluation of patients with EE resulting in
a specific diagnosis is of great value. We want to emphasize
the importance of genetic analysis in the early diagnostic
efforts of these patients. WES is a very powerful, non-
invasive, accessible, and not overly expensive diagnostic tool.
The finding of a specific gene mutation is of exceptional
importance to clinicians for further management, and for the
family to cope with the diagnosis and prognosis. Genetic
counselling about familial risk, as well as for potential pre-
natal diagnostics, is of great value to the family.
Although the field of mitochondrial encephalomyopathies
is highly dynamic, the genetic diagnosis of these disorders,
which may offer the possibility to design targeted therapy,
remains challenging. In the near future, the WES approach
will provide valuable information regarding the genes impli-
cated in MRC defects, which are important in the differential
diagnosis of EE.
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